

Ø110

M E M O R A N D U M

TO: Dr. R. PerryFROM: Dr. P. Foster

c.c. Dr. J. D. Cash

SUBJECT: FVIII & Ca²⁺DATE: 2nd April, 1985

At the recent meeting of the FVIII Study Group it was agreed that a clinical trial of the intermediate-purity concentrate prepared with and without calcium was still important. However, it was also agreed that this material would now have to be heat treated (68°C, 2 hrs). This has been carried out with the following results.

	NY 4013-1	NY 4014-1 (+Ca ²⁺)
FVIII C (u/ml)		
1-stage	7.46, 7.60	9.68, 10.08
2-stage	7.43, 6.95	8.35, 8.09
Chromogenic	8.40, 8.65	10.27, 9.78
Vial Content (iu)		
1-stage	161	211
2-stage	154	176
Chromogenic	182	214
Number of vials	188	186
Solubility (mins)	8, 16	8

Hence the addition of calcium has increased potency by:-

31% (1-stage)
14% (2-stage)
18% (chromogenic)

This material is now available for issue with about 180 vials in each lot.